MedTrace Logo

Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

NCT05909488 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-25

No results posted yet for this study

Summary

The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.

Conditions

Interventions

BIOLOGICAL

5 x 10^6 UC-MSC + CM

5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)

BIOLOGICAL

1.5 x 10^6 UC-MSC + CM

1.5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)

Sponsors & Collaborators

  • PT. Prodia Stem Cell Indonesia

    lead INDUSTRY

Principal Investigators

  • dr. Muhammad B Sasongko, Sp.M, M.Epid, PhD · Gadjah Mada University, Faculty of Medicine

  • Cosmos Mangunsong, Doctor · Jakarta Eye Center

  • dr. Rifa Widyaningrum, M.Sc, PhD · Sardjito Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-07-31
Completion
2027-09-30

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05909488 on ClinicalTrials.gov